Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‐induced apoptosis and reverses the malignant phenotype of glioblastoma cells
Keywords: 
HDAC6
Tubastatin A
Temozolomide
Glioblastoma
Sonic hedgehog
Issue Date: 
2019
Publisher: 
Spandidos publications
ISSN: 
1791-2423
Citation: 
Urdiciain-Ezpeleta, A. (Alejandro); Erausquin, E. (Elena); Meléndez, B. (Bárbara); et al. "Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‐induced apoptosis and reverses the malignant phenotype of glioblastoma cells". International journal of oncology. 54 (5), 2019, 1797 - 1808
Abstract
Glioblastoma or grade IV astrocytoma is the most common and lethal form of glioma. Current glioblastoma treatment strategies use surgery followed by chemotherapy with temozolomide. Despite this, numerous glioblastoma cases develop resistance to temozolomide treatments, resulting in a poor prognosis for the patients. Novel approaches are being investigated, including the inhibition of histone deacetylase 6 (HDAC6), an enzyme that deacetylates α-tubulin, and whose overexpression in glioblastoma is associated with the loss of primary cilia. The aim of the present study was to treat glioblastoma cells with a selective HDAC6 inhibitor, tubastatin A, to determine if the malignant phenotype may be reverted. The results demonstrated a notable increase in acetylated α-tubulin levels in treated cells, which associated with downregulation of the sonic hedgehog pathway, and may hypothetically promote ciliogenesis in those cells. Treatment with tubastatin A also reduced glioblastoma clonogenicity and migration capacities, and accelerated temozolomide-induced apoptosis. Finally, HDAC6 inhibition decreased the expression of mesenchymal markers, contributing to reverse epithelial-mesenchymal transition in glioblastoma cells.

Files in This Item:
Thumbnail
File
ijo_54_5_1797_PDF (1).pdf
Description
Size
1.28 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.